| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Lung and Thoracic cancer
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Kang
Cancer Res Treat. 2024;56(1):48-60.   Published online June 27, 2023    DOI: https://doi.org/10.4143/crt.2023.453
                        Supplementary      
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2020;52(4):1288-1290.   Published online June 22, 2020    DOI: https://doi.org/10.4143/crt.2020.278
                           Web of Science 17  Crossref 7
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Journal Impact Factor 4.6
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI